Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in bladder and colon cancer.
Tenascin C has been recently suggested as a tumor marker, however, its levels in serum has been evaluated only in patients with head and neck cancer and melanoma. In this study, we investigated Tenascin C expression in blood samples from colorectal and bladder cancer patients, compared to that of epidermal growth factor receptor (EGFR), a known circulating tumor marker in these cancer types. RT-PCR specific for Tenascin C and EGFR was performed on RNAs extracted from blood samples of 60 patients affected by colon or bladder cancer. We then investigated the statistical association between Tenascin C, EGFR expression and disease-free survival using the Kaplan-Meier method. Furthermore, in order to select which variable between EGFR and Tenascin C was the most predictive for recurrence, a Cox model for proportional risk was applied. Among all patients analysed, a significantly higher disease-free time was found in the group negative for both EGFR and Tenascin C expression; EGFR expression was significantly correlated to disease progression in stages III and IV, whereas in all patients with stage I and II disease Tenascin C correlated better with prognosis. Negative expression of both EGFR and Tenascin C identifies a group of patients with poor tendency to disease recurrence and longer relapse-free time. While Tenascin C expression seems to influence prognosis in patients with low-stage disease, EGFR appears a marker of worse prognosis in patients with high-staged tumors.
Gazzaniga
Paola
P
Department of Experimental Medicine and Pathology, University of the Study of Rome-La Sapienza, Viale Regina Elena 324, 00161 Rome, Italy.
Nofroni
Italo
I
Gandini
Orietta
O
Silvestri
Ida
I
Frati
Luigi
L
Aglianò
Anna Maria
AM
Gradilone
Angela
A
D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000097:blood*; D002277:Carcinoma / Q000235:genetics* / Q000473:pathology*; D003110:Colonic Neoplasms / Q000235:genetics* / Q000473:pathology*; D066246:ErbB Receptors / Q000096:biosynthesis* / Q000097:blood*; D006801:Humans; D008962:Models, Theoretical; D009367:Neoplasm Staging; D009360:Neoplastic Cells, Circulating; D011379:Prognosis; D012307:Risk Factors; D016019:Survival Analysis; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000473:pathology*
D014408:Biomarkers, Tumor; D066246:ErbB Receptors